FDA‑Approved Foundayo Oral GLP‑1 Obesity Drug to Be Sold via TrumpRx Pricing Platform
The FDA has approved Eli Lilly’s oral GLP‑1 obesity pill, orforglipron (brand name Foundayo), in a 50‑day expedited review; clinical trial data showed a mean ~11.2% weight loss (≈25 lbs) at the highest dose over more than 16 months versus ~2.1% for placebo, with higher GI‑related discontinuations and a thyroid‑tumor/cancer warning. Foundayo will be sold through the Trump administration’s TrumpRx pricing platform (and Lilly’s channels), with coupons and list pricing roughly $149–$349 per month for uninsured patients and expected out‑of‑pocket costs around $25 for privately insured and about $50 for Medicare beneficiaries; shipments could begin April 6, and the pill can be taken without fasting or timing restrictions unlike oral Wegovy.
📌 Key Facts
- The FDA has approved Eli Lilly’s oral GLP‑1 obesity pill Foundayo (generic: orforglipron), granted under a new expedited/priority review program that completed in 50 days.
- Foundayo is an oral GLP‑1 that mimics natural appetite hormones and — unlike the competing oral Wegovy pill — can be taken any time of day without fasting or timing restrictions.
- Clinical trials showed large average weight losses on higher doses (about 11–12% of body weight — roughly 25–27 pounds — versus ~2.1% on placebo over ~16 months); discontinuations for gastrointestinal side effects were higher on orforglipron (about 5–10% vs ~3% on placebo).
- Lilly warns of a thyroid‑tumor/cancer risk and an expanded side‑effect profile that includes extensive gastrointestinal symptoms and reports of hair loss.
- U.S. cash prices reported range roughly $149–$349 per month depending on dose; insured patients may pay about $25/month via Lilly discount programs, while the White House projects Medicare patients around $50 and privately insured about $25 if purchased through the TrumpRx platform.
- Foundayo will be offered on President Trump’s TrumpRx federal drug price‑comparison platform (positioned as a ‘one‑stop shop’ that the White House says has broader reach than Lilly Direct); TrumpRx coupons for uninsured patients were reported starting at $149 for the first dose with higher refill/pricing tiers.
- The pill could appear on TrumpRx as soon as Thursday, with Eli Lilly shipping starting April 6; markets reacted positively to the approval (Lilly stock rose more than 4% in afternoon trading).
- Context: more than 600,000 prescriptions have been written for Novo Nordisk’s oral Wegovy since December, and surveys show substantial use of injectable GLP‑1s (about 1 in 8 U.S. adults), while experts and Lilly’s CEO have commented publicly that an oral GLP‑1 could improve access and reduce stigma around obesity treatment.
📊 Relevant Data
Compared to White patients, Black patients had adjusted odds ratios of 0.7 for tirzepatide prescriptions, 0.8 for semaglutide, and 1.0 for dulaglutide, indicating lower likelihood of receiving these GLP-1 medications in 2022-2023.
In a study of U.S. military veterans, Black patients had 26% lower odds of receiving semaglutide prescriptions for diabetes and 9% lower for non-diabetes compared to White patients in 2024.
US minority veterans face unequal access to Ozempic and Wegovy, study finds — Reuters
Black adults with obesity had a higher prevalence of the SEMA4D genetic variant (55.6% vs. 22.9% without the variant) and higher mean BMI (31.9 kg/m² vs. 26.62 kg/m²) in a 2017 study replicated in 9,020 Black U.S. residents.
Genetics and racism contribute to racial-ethnic disparities in obesity and comorbidities — Healio
Factors contributing to racial disparities in obesity include disparities in income, education, access to health insurance, housing, healthy food, and racism-related stress, leading to higher obesity and diabetes rates in Black Americans.
New obesity drugs seem to be everywhere. Black America feels left out — STAT
📰 Source Timeline (5)
Follow how coverage of this story developed over time
- Foundayo will be offered on President Trump’s federal drug cost-comparison website TrumpRx (Trump Rx), with coupons for uninsured Americans starting at $149 for the first dose, $199 for a refill, and $299 for future prescriptions.
- The White House expects Medicare patients to pay around $50 and privately insured Americans about $25 for Foundayo, positioning TrumpRx as a pricing and access hub for GLP-1 drugs.
- A White House official claims TrumpRx has greater reach than Eli Lilly’s Lilly Direct platform and aims to serve as a ‘one stop shop’ to compare all GLP-1 drugs on the market.
- The article reaffirms that Foundayo is the first drug approved under the FDA’s new priority voucher program, with review completed in 50 days, and says the pill could appear on TrumpRx as soon as Thursday, with Eli Lilly shipping starting April 6.
- Fox article emphasizes that Foundayo is currently the only GLP‑1 weight‑loss pill that can be taken at any time of day without food or water restrictions, contrasting it with oral Wegovy.
- Cites Eli Lilly press‑release data that patients on the highest Foundayo dose lost an average of 27.3 pounds, or 12.4% of body weight, in clinical trials.
- Details a broader development program: Foundayo is being studied for type 2 diabetes, obstructive sleep apnea, osteoarthritis knee pain, hypertension, peripheral artery disease and stress urinary incontinence.
- Includes new on‑the‑record quotes from Deborah Horn (UTHealth Houston) and Lilly CEO David Ricks about access barriers, stigma and how an oral GLP‑1 could “level the playing field” for obesity treatment.
- Spells out Lilly’s thyroid‑tumor and thyroid‑cancer warning and lists an expanded side‑effect profile, including hair loss and extensive gastrointestinal symptoms.
- This CBS item confirms in general terms that the FDA has approved a new Eli Lilly GLP‑1 weight‑loss drug but provides no additional specifics beyond what the earlier detailed story already carried.
- The segment is framed as an explainer by Dr. Jon LaPook rather than adding new trial data, pricing figures, or regulatory nuances.
- No new quotes from FDA officials or Eli Lilly executives are included in the text provided.
- Confirms the generic name orforglipron and reiterates the brand name Foundayo as a GLP‑1 pill mimicking natural appetite hormones.
- Specifies that FDA completed its review in 50 days under a new expedited-approval program aimed at cutting drug approval times.
- Provides concrete U.S. cash pricing ranges: $149–$349 per month depending on dose, with insured patients potentially paying $25/month via a Lilly discount card.
- States that more than 600,000 prescriptions have already been written for Novo Nordisk’s competing oral Wegovy pill since its December approval.
- Details that about 1 in 8 people in the U.S. have used injectable GLP‑1 drugs, citing a KFF survey.
- Clarifies that Foundayo will be included in a Trump administration deal to lower prices on GLP‑1 drugs.
- Reports that Eli Lilly’s stock rose more than 4% in Wednesday afternoon trading after the approval.
- Adds exact trial outcome wording from NEJM: 11.2% mean weight loss (~25 pounds) at 36 mg over more than 16 months vs 2.1% (~<5 pounds) on placebo, and that 5–10% of patients on orforglipron discontinued due to GI side effects vs nearly 3% on placebo.
- Reiterates usage distinction: orforglipron can be taken without fasting or timing restrictions, while the Wegovy pill must be taken on an empty stomach with a 30‑minute wait before eating or drinking.